Compare ECF & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECF | GNLX |
|---|---|---|
| Founded | 1986 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.3M | 202.4M |
| IPO Year | N/A | 2023 |
| Metric | ECF | GNLX |
|---|---|---|
| Price | $11.78 | $4.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | 57.7K | ★ 140.8K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.02 | $1.99 |
| 52 Week High | $8.91 | $8.54 |
| Indicator | ECF | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 40.94 |
| Support Level | $11.74 | $4.20 |
| Resistance Level | $11.95 | $4.37 |
| Average True Range (ATR) | 0.22 | 0.25 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 72.97 | 46.90 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.